Clindene 75 Tablets

국가: 오스트레일리아

언어: 영어

출처: APVMA (Australian Pesticides and Veterinary Medicines Authority)

유효 성분:

CLINDAMYCIN AS CLINDAMYCIN HYDROCHLORIDE

제공처:

DECHRA VETERINARY PRODUCTS (AUSTRALIA) PTY. LTD.

약제 형태:

ORAL TABLET

구성:

CLINDAMYCIN AS CLINDAMYCIN HYDROCHLORIDE ANTIBIOTIC Active 75.0 mg/Tb

패키지 단위:

100 tablets

수업:

VM - Veterinary Medicine

치료 영역:

ANTIBIOTIC & RELATED

제품 요약:

Poison schedule: 4; Withholding period: ; Host/pest details: CAT: [ABSCESSES (CAUSED BY BACTERIA SUSCEPTIBLE TO CLINDAMYCIN), BACTEROIDES SPP., CLOSTRIDIUM SPP., DENTAL INFECTIONS (CAUSED BY BACTERIA SUSCEPTIBLE TO CLINDAMYCIN), FUSOBACTERIUM SPP., OSTEOMYELITIS (CAUSED BY BACTERIA SUSCEPTIBLE TO CLINDAMYCIN), PEPTOSTREPTOCOCCUS SPP., PROPIONIBACTERIUM SPP., STAPHYLOCOCCUS AUREUS, STAPHYLOCOCCUS SPP., STREPTOCOCCUS SPP., WOUNDS (CAUSED BY BACTERIA SUSCEPTIBLE TO CLINDAMYCIN)]; DOG: [ABSCESSES (CAUSED BY BACTERIA SUSCEPTIBLE TO CLINDAMYCIN), BACTEROIDES SPP., CLOSTRIDIUM SPP., DENTAL INFECTIONS (CAUSED BY BACTERIA SUSCEPTIBLE TO CLINDAMYCIN), FUSOBACTERIUM SPP., OSTEOMYELITIS (CAUSED BY BACTERIA SUSCEPTIBLE TO CLINDAMYCIN), PEPTOSTREPTOCOCCUS SPP., PROPIONIBACTERIUM SPP., STAPHYLOCOCCUS AUREUS, STAPHYLOCOCCUS SPP., STREPTOCOCCUS SPP., WOUNDS (CAUSED BY BACTERIA SUSCEPTIBLE TO CLINDAMYCIN)]

승인 상태:

Registered

승인 날짜:

2023-07-01

환자 정보 전단

Clindene 75 Tablets
87331/140183
Product Name:
APVMA Approval No:
Label Name:
CLINDENE 75 TABLETS
Signal Headings:
PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
Constituent
Statements:
Each tablet contains: 75 mg CLINDAMYCIN (as clindamycin hydrochloride)
Claims:
For treatment of dental infections, wounds, abscesses and
osteomyelitis caused by
bacteria susceptible to clindamycin in dogs and cats. Resistance can
develop to any
antibiotic.
Net Contents:
100 tablets
Directions for Use:
Restraints:
DO NOT USE in food producing species of animals or horses.
DO NOT USE in guinea pigs, hamsters, rabbits or ruminants.
Contraindications:
This product is contraindicated in animals with a history of
hypersensitivity to Clindamycin
or Lincomycin.
Precautions:
Antagonism has been reported between Clindamycin and Erythromycin.
Periodic monitoring of hepatic and renal function as well as complete
blood counts should
be undertaken with prolonged (greater than one month) therapy.
Use with caution in patients with severe hepatic and or renal
disturbances accompanied
by metabolic aberrations. Such patients should have hepatic and renal
function monitored
during high dose therapy.
Clindamycin has been shown to have neuromuscular blocking properties.
Use with caution
in animals receiving neuromuscular blocking agents.
The safety of Clindamycin has not been established in breeding
animals.
Side Effects:
Clindamycin may cause overgrowth of non-susceptible organisms such as
resistant
Clostridium spp and yeasts. RLP APPROVED
Vomiting and diarrhoea have occasionally been observed.
Dosage and
Administration:
For oral administration only.
For the treatment of dental infections, wounds and abscesses
administer 5.5mg/kg
bodyweight twice daily or 11mg/kg bodyweight once daily for 7-10 days.
Treatment may be
extended up to 28 days. If no clinical improvement is observed within
4 days the sensitivity
of the pathogen should be redetermined.
For the treatment of osteomyelitis administer 11mg/kg bodyweight twice